secwatch / observer
8-K filed March 9, 2023, 6:59 PM ET ticker IRIX CIK 0001006045
earnings confidence high sentiment neutral materiality 0.65

Iridex Q4 revenue flat at $15.2M; record glaucoma probe sales; FY net loss widens to $7.5M

IRIDEX CORP

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IRIDEX CORP reported the three months ended December 31, 2022 results: revenue $15.2 million, net income $1.1 million, EPS $0.07 per share.

Period
the three months ended December 31, 2022
Revenue
$15.2 million
Net income
$1.1 million
EPS
$0.07 per share
Result
reported results
Exact text from the filing
results for the fourth quarter and year ended December 31, 2022 and issued 2023 financial guidance. Fourth Quarter 2022 & Recent Highlights • Generated total revenue of $15.2 million, essentially unchanged from the prior year period • Cyclo G6® product family revenue of $4.2 million, an increase of 9% year-over-year o 16,400 Cyclo G6 probes sold, a quarterly
View on SEC.gov
Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IRIDEX CORP reported full year 2023 results: revenue $57 million to $59 million. Guidance initiated.

Period
full year 2023
Revenue
$57 million to $59 million
Guidance
initiated
Result
guidance update
Exact text from the filing
Total revenue for the full year is expected to be $57 million to $59 million.
View on SEC.gov
Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IRIDEX CORP reported the year ended December 31, 2022 results: revenue $57.0 million, net income $7.5 million, EPS $0.47 per share.

Period
the year ended December 31, 2022
Revenue
$57.0 million
Net income
$7.5 million
EPS
$0.47 per share
Result
reported results
Exact text from the filing
577 systems in February 2023 • Cash and cash equivalents totaled approximately $13.9 million as of December 31, 2022 Full Year 2022 Highlights • Generated total revenue of $57.0 million, an increase of 6% compared to 2021 • Cyclo G6 product family revenue of $14.7 million, an increase of 5% year-over-year • Sold 59,800 Cyclo G6 probes, compared to 58,200 in the
View on SEC.gov

Browse all earnings releases →

IRIDEX CORP filing history →

Source: SEC EDGAR
accession 0000950170-23-007036
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.